Lanadelumab - Takeda
Alternative Names: Anti-plasma kallikrein mAb; Anti-plasma kallikrein monoclonal antibody; DX-2930; Lanadelumab-flyo; OHB-401; SHP 643; TAK-743; TAKHZYRO; TakhzyroLatest Information Update: 28 Feb 2024
At a glance
- Originator Dyax
- Developer Amgen; Dyax; Oak Hill Bio; Takeda; UCB
- Class Antivirals; Eye disorder therapies; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Plasma kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hereditary angioedema
- Phase III COVID 2019 infections
- Phase I Diabetic macular oedema
- No development reported COVID-19 pneumonia
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in COVID-19 pneumonia in USA (IV, Infusion)
- 28 Nov 2023 Takeda completes a Phase-III clinical trials in Hereditary angioedema (In children, In adolescents, In adults) in China (SC) (NCT05460325)
- 17 Nov 2023 European Commission approves label update for TAKHZYRO® (lanadelumab) for Hereditary angioedema (In children, Prevention) in EU